<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5335">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037489</url>
  </required_header>
  <id_info>
    <org_study_id>MIV-711-202</org_study_id>
    <nct_id>NCT03037489</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients</brief_title>
  <official_title>An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients With Knee Joint Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medivir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label, one-arm Phase II extension study to evaluate the safety
      and tolerability of MIV-711 in patients with knee joint osteoarthritis (OA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MIV-711 in OA patients</measure>
    <time_frame>26 weeks</time_frame>
    <description>AE/SAE
measuring the number of AEs
summarizing the severities of AEs
measuring the number of AEs related to treatment
summarizing the severities of AEs related to treatment
measuring the number and severity of SAEs
measuring the number and severity of SAEs related to treatment
Labs
Number of abnormals
Number of grade 3 or 4 (if grading lab results)
Change from baseline
ECGS
Number of abnormals
Change from baseline
Number of pts with prolonged QTc
Etc
PE
Number of abnormals
Change from baseline
Vitals
BP
Heart rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>MIV-711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MIV-711 for a total of 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIV-711</intervention_name>
    <description>MIV-711 administered orally once daily</description>
    <arm_group_label>MIV-711</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Previously enrolled in the MIV-711-201 study including completion of Visit 8 either by

          -  Receiving MIV-711 200 mg and had non-significant clinical worsening on the primary
             endpoint as defined by NRS increase of ≤2 OR by

          -  Receiving placebo and had a clinically significant worsening on the primary endpoint
             as defined by NRS increase of ≥2

        Exclusion Criteria:

          -  The presence of any inflammatory arthritis

          -  Any generalized pain condition that may interfere with the evaluation of the target
             knee pain (e.g., fibromyalgia) as judged by the investigator.

          -  Any clinically severe or significant uncontrolled concurrent illness, which, in the
             opinion of the Investigator, would impair ability to give informed consent or take
             part in or complete this clinical study.

          -  Known or suspected intolerance or hypersensitivity to the investigational product,
             closely related compounds, or any of the stated ingredients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Conaghan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Öhd</last_name>
    <phone>+46-854683100</phone>
    <email>john.ohd@medivir.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Wadell</last_name>
    <phone>+46-8-54683100</phone>
    <email>cecilia.wadell@medivir.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MC Comac Medical</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekaterina Raykova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LCC ARENSIA Exploratory Medicine</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nino Tsiskarishvili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAREXEL Berlin Early Phase Clinical Unit</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sara Armani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LCC ARENSIA Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inga Bodrug</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>December 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
